Evidence map›Paper›PMID 35672530›Full record

ArticleJournal of neuro-oncology2022

Time interval between the diagnosis of breast cancer and brain metastases impacts prognosis after metastasis surgery.

Anna Michel, Thiemo Florin Dinger, Alejandro N Santos, Daniela Pierscianek, Marvin Darkwah Oppong, Yahya Ahmadipour, Philipp Dammann, Karsten H Wrede, Jörg Hense, Christoph Pöttgen and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Radiotherapy in breast cancer brain metastases: the impact of time interval and disease dynamics when breast cancer seeds to the brain.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Anna MichelDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany. anna.michel@uk-essen.de.
Thiemo Florin DingerDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Alejandro N SantosDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Daniela PierscianekDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Marvin Darkwah OppongDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Yahya AhmadipourDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Philipp DammannDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Karsten H WredeDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Jörg HenseDepartment of Medical Oncology, University Hospital Essen, Essen, Germany.
Christoph PöttgenDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
Antonella IannacconeDepartment of Obstetrics and Gynecology, University Hospital Essen, Essen, Germany.
Rainer KimmigDepartment of Obstetrics and Gynecology, University Hospital Essen, Essen, Germany.
Ulrich SureDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Ramazan JabbarliDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Essen University Hospital · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBreast cancer (BC) is the most frequently diagnosed tumor entity in women. Occurring at different time intervals (TI) after BC diagnosis, brain metastases (BM) are associated with poor prognosis. We aimed to identify the risk factors related to and the clinical impact of timing on overall survival (OS) after BM surgery.

methodsWe included 93 female patients who underwent BC BM surgery in our institution (2008-2019). Various clinical, radiographic, and histopathologic markers were analyzed with respect to TI and OS.

resultsThe median TI was 45.0 months (range: 9-334.0 months). Fifteen individuals (16.1%) showed late occurrence of BM (TI ≥ 10 years), which was independently related to invasive lobular BC [adjusted odds ratio (aOR) 9.49, 95% confidence interval (CI) 1.47-61.39, p = 0.018] and adjuvant breast radiation (aOR 0.12, 95% CI 0.02-0.67, p = 0.016). Shorter TI (< 5 years, aOR 4.28, 95% CI 1.46-12.53, p = 0.008) was independently associated with postoperative survival and independently associated with the Union for International Cancer Control stage (UICC) III-IV of BC (aOR 4.82, 95% CI 1.10-21.17, p = 0.037), midline brain shift in preoperative imaging (aOR10.35, 95% CI 1.09-98.33, p = 0.042) and identic estrogen receptor status in BM (aOR 4.56, 95% CI 1.35-15.40, p = 0.015).

conclusionsSeveral factors seem to influence the period between BC and BM. Occurrence of BM within five years is independently associated with poorer prognosis after BM surgery. Patients with invasive lobular BC and without adjuvant breast radiation are more likely to develop BM after a long progression-free survival necessitating more prolonged cancer aftercare of these individuals.

Indexed as

Brain NeoplasmsBreast NeoplasmsFemaleHumansPrognosisRadiotherapy, AdjuvantRetrospective StudiesBrain metastasisBrain metastasis surgeryBreast cancerInvasive loboluar breast cancerTime interval

Identifiers

PMID35672530
PMCPMC9325855
OpenAlexW4281710555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.